Co‐occurring mutations with smoking‐related canonical mutations, such as KRAS, STK11, and KEAP1, are common in patients with SMARCA4 mutations, and up to 44% of these patients exhibit a smoking‐related co‐mutation signature and a high tumor mutational burden [12, 28]. This evidence concerns the gene KRAS and neoplasm.